The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multice...
Uloženo v:
| Vydáno v: | Nature medicine Ročník 27; číslo 11; s. 1954 - 1960 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
New York
Nature Publishing Group US
01.11.2021
Nature Publishing Group |
| Témata: | |
| ISSN: | 1078-8956, 1546-170X, 1546-170X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2,
P
= 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6,
P
= 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0,
P
= 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7,
P
= 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8,
P
= 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85,
P
= 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42,
P
= 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF.
In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking. |
|---|---|
| AbstractList | In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF.Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3-9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0-9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7-10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6-34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1-7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05-2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01-1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multicenter, randomized trial of patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin improves the primary endpoint of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS), a measure of heart failure-related health status, at 12 weeks after treatment initiation. Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS), clinically meaningful changes in KCCQ-CS and -OS, and changes in weight, natriuretic peptides, glycated hemoglobin and systolic blood pressure. In total, 324 patients were randomized to dapagliflozin or placebo. Dapagliflozin improved KCCQ-CS (effect size, 5.8 points (95% confidence interval (CI) 2.3–9.2, P = 0.001), meeting the predefined primary endpoint, due to improvements in both KCCQ total symptom score (KCCQ-TS) (5.8 points (95% CI 2.0–9.6, P = 0.003)) and physical limitations scores (5.3 points (95% CI 0.7–10.0, P = 0.026)). Dapagliflozin also improved 6MWT (mean effect size of 20.1 m (95% CI 5.6–34.7, P = 0.007)), KCCQ-OS (4.5 points (95% CI 1.1–7.8, P = 0.009)), proportion of participants with 5-point or greater improvements in KCCQ-OS (odds ratio (OR) = 1.73 (95% CI 1.05–2.85, P = 0.03)) and reduced weight (mean effect size, 0.72 kg (95% CI 0.01–1.42, P = 0.046)). There were no significant differences in other secondary endpoints. Adverse events were similar between dapagliflozin and placebo (44 (27.2%) versus 38 (23.5%) patients, respectively). These results indicate that 12 weeks of dapagliflozin treatment significantly improved patient-reported symptoms, physical limitations and exercise function and was well tolerated in chronic HFpEF. In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking. |
| Audience | Academic |
| Author | Ryan, John J. Pursley, Michael Windsor, Sheryl L. Gordon, Robert A. Sharma, Kavita Joseph, Susan M. Tang, Fengming Chaudhry, Sunit-Preet Chandra, Lokesh Fong, Michael Kosiborod, Mikhail N. Malik, Ali O. Kanwar, Manreet K. Shah, Sanjiv J. Lamba, Sumant Siraj, Elias S. Umpierrez, Guillermo Khan, Sadiya S. Chow, Chen H. Clemson, Barry S. Nassif, Michael E. Borlaug, Barry A. Khariton, Yevgeniy Lewis, Gregory D. Kitzman, Dalane W. Khumri, Taiyeb |
| Author_xml | – sequence: 1 givenname: Michael E. surname: Nassif fullname: Nassif, Michael E. organization: Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City – sequence: 2 givenname: Sheryl L. surname: Windsor fullname: Windsor, Sheryl L. organization: Saint Luke’s Mid America Heart Institute – sequence: 3 givenname: Barry A. orcidid: 0000-0001-9375-0596 surname: Borlaug fullname: Borlaug, Barry A. organization: Department of Cardiovascular Medicine, Mayo Clinic – sequence: 4 givenname: Dalane W. surname: Kitzman fullname: Kitzman, Dalane W. organization: Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics, Wake Forest School of Medicine – sequence: 5 givenname: Sanjiv J. orcidid: 0000-0002-5655-8201 surname: Shah fullname: Shah, Sanjiv J. organization: Division of Cardiology, Department of Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine – sequence: 6 givenname: Fengming surname: Tang fullname: Tang, Fengming organization: Saint Luke’s Mid America Heart Institute – sequence: 7 givenname: Yevgeniy surname: Khariton fullname: Khariton, Yevgeniy organization: Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City – sequence: 8 givenname: Ali O. surname: Malik fullname: Malik, Ali O. organization: Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City – sequence: 9 givenname: Taiyeb surname: Khumri fullname: Khumri, Taiyeb organization: Saint Luke’s Mid America Heart Institute – sequence: 10 givenname: Guillermo surname: Umpierrez fullname: Umpierrez, Guillermo organization: Emory University – sequence: 11 givenname: Sumant surname: Lamba fullname: Lamba, Sumant organization: First Coast Cardiovascular Institute – sequence: 12 givenname: Kavita surname: Sharma fullname: Sharma, Kavita organization: Johns Hopkins University School of Medicine – sequence: 13 givenname: Sadiya S. surname: Khan fullname: Khan, Sadiya S. organization: Division of Cardiology, Department of Medicine and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine – sequence: 14 givenname: Lokesh surname: Chandra fullname: Chandra, Lokesh organization: Chicago Medical Research – sequence: 15 givenname: Robert A. surname: Gordon fullname: Gordon, Robert A. organization: NorthShore University HealthSystem – sequence: 16 givenname: John J. surname: Ryan fullname: Ryan, John J. organization: University of Utah – sequence: 17 givenname: Sunit-Preet surname: Chaudhry fullname: Chaudhry, Sunit-Preet organization: Ascension St. Vincent – sequence: 18 givenname: Susan M. surname: Joseph fullname: Joseph, Susan M. organization: Division of Cardiovascular Medicine, University of Maryland School of Medicine – sequence: 19 givenname: Chen H. surname: Chow fullname: Chow, Chen H. organization: Stormont Vail Health – sequence: 20 givenname: Manreet K. surname: Kanwar fullname: Kanwar, Manreet K. organization: Cardiovascular Institute, Allegheny Health Network – sequence: 21 givenname: Michael surname: Pursley fullname: Pursley, Michael organization: Heart Group of the Eastern Shore – sequence: 22 givenname: Elias S. surname: Siraj fullname: Siraj, Elias S. organization: Eastern Virginia Medical School – sequence: 23 givenname: Gregory D. surname: Lewis fullname: Lewis, Gregory D. organization: Cardiology Division, Massachusetts General Hospital – sequence: 24 givenname: Barry S. surname: Clemson fullname: Clemson, Barry S. organization: OSF HealthCare Cardiovascular Institute – sequence: 25 givenname: Michael orcidid: 0000-0002-0874-7059 surname: Fong fullname: Fong, Michael organization: University of Southern California – sequence: 26 givenname: Mikhail N. orcidid: 0000-0002-3750-9789 surname: Kosiborod fullname: Kosiborod, Mikhail N. email: mkosiborod@saint-lukes.org organization: Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City, The George Institute for Global Health, University of New South Wales |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34711976$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkm9r1TAUxotM3B_9Ar6QgiD6ojNpmzbxhTCGzsGFgbuK70KanrYZucldks7rPr3p7tx2x2VICDkkv-ecJOfZT3aMNZAkrzE6xKigH32JCcMZyuPEpKiy1bNkD5OyynCNfu3EGNU0o4xUu8m-9xcIoQIR9iLZLcoaY1ZXe4mfD5Cen8zmearMoBoVrEtbsRS9Vp2218rE_XQA4ULaCaVHB-lvFYZ06cCDu4I2hQuQQVmTdk7cBJ9SkS5GHZQEE8ClTpjWLtR1ZINTQr9MnndCe3h1ux4kP75-mR9_y2ZnJ6fHR7NMVjUNGROoqXNcIAaklg1qu4JQ1pCmk50oaQuIVPEHsKzbGggrqWBCtKzLhWxxJXBxkHxe512OzQLa6TZOaL50aiHcH26F4psnRg28t1ecVqiscxITvL9N4OzlCD7whfIStBYG7Oh5ThjCecnIVOvtI_TCjs7E500Uy-s8p-ie6oUGrkxnY105JeVHFS1ySktWRCrbQvVgIF4yWqBTcXuDP9zCx9HCQsmtgg8bgsgEWIVejN7z0_Pv_8-e_dxk3z1go2l0GLzV42QKvwm-ediZu5b882UE8jUgnfXeQXeHYMQn8_O1-Xk0P78xP19FEX0kkiqIqXj8D6WflhZrqY91TA_uvn1PqP4C7qIXlw |
| CitedBy_id | crossref_primary_10_1007_s10741_024_10438_2 crossref_primary_10_1007_s00210_024_03053_3 crossref_primary_10_3389_fendo_2023_1069715 crossref_primary_10_1038_s41572_024_00540_y crossref_primary_10_1155_2022_5834218 crossref_primary_10_1093_eurheartj_ehae490 crossref_primary_10_1007_s40256_022_00550_9 crossref_primary_10_1016_j_jchf_2023_07_014 crossref_primary_10_3389_fcvm_2022_1021346 crossref_primary_10_3390_healthcare12232464 crossref_primary_10_1016_j_tjnut_2024_08_006 crossref_primary_10_1093_eurheartj_ehae479 crossref_primary_10_1038_s44161_022_00032_w crossref_primary_10_14797_mdcvj_1162 crossref_primary_10_1016_j_hfc_2022_03_010 crossref_primary_10_3390_ijms26104781 crossref_primary_10_2337_dc23_S010 crossref_primary_10_1016_j_jchf_2022_05_009 crossref_primary_10_7759_cureus_86368 crossref_primary_10_1093_ndt_gfae158 crossref_primary_10_1016_j_jchf_2024_02_020 crossref_primary_10_1161_JAHA_123_032279 crossref_primary_10_1080_14656566_2022_2143263 crossref_primary_10_1016_j_ejphar_2024_176875 crossref_primary_10_3389_fphar_2025_1532123 crossref_primary_10_1007_s10741_025_10553_8 crossref_primary_10_3390_ijms24054903 crossref_primary_10_1002_phar_2839 crossref_primary_10_3390_jcm14113948 crossref_primary_10_1016_j_jacc_2024_10_111 crossref_primary_10_1016_j_cardfail_2021_12_013 crossref_primary_10_3390_jpm12101698 crossref_primary_10_1002_adbi_202300199 crossref_primary_10_1016_j_jacc_2023_01_049 crossref_primary_10_1016_j_jacc_2024_09_023 crossref_primary_10_4103_ATMR_ATMR_173_24 crossref_primary_10_1161_JAHA_122_026301 crossref_primary_10_1016_j_rec_2022_04_019 crossref_primary_10_1093_ndt_gfae058 crossref_primary_10_1186_s12933_022_01574_w crossref_primary_10_1186_s44158_023_00094_7 crossref_primary_10_1093_eurheartj_ehad118 crossref_primary_10_1016_j_cpcardiol_2022_101156 crossref_primary_10_59556_japi_71_0440 crossref_primary_10_1016_j_amjmed_2022_02_043 crossref_primary_10_3389_fphar_2022_910858 crossref_primary_10_14797_mdcvj_1120 crossref_primary_10_1161_CIRCRESAHA_123_322381 crossref_primary_10_1007_s10741_023_10363_w crossref_primary_10_4239_wjd_v14_i6_724 crossref_primary_10_1007_s10741_024_10385_y crossref_primary_10_1007_s40256_024_00641_9 crossref_primary_10_1161_CIRCULATIONAHA_123_067505 crossref_primary_10_1038_s41598_023_45390_y crossref_primary_10_1001_jamainternmed_2022_5010 crossref_primary_10_1093_eurheartj_ehad345 crossref_primary_10_1186_s12933_025_02679_8 crossref_primary_10_1038_s41574_025_01170_4 crossref_primary_10_1111_dom_14805 crossref_primary_10_1056_NEJMc2406233 crossref_primary_10_1080_02648725_2023_2204704 crossref_primary_10_3390_antiox13111330 crossref_primary_10_1002_jcu_23559 crossref_primary_10_1016_j_cardfail_2025_02_014 crossref_primary_10_1016_j_jchf_2025_102566 crossref_primary_10_1016_j_jacc_2024_04_038 crossref_primary_10_1016_j_cpcardiol_2023_101817 crossref_primary_10_1111_aor_14850 crossref_primary_10_1016_j_jacadv_2025_101891 crossref_primary_10_1111_jce_16344 crossref_primary_10_1016_j_cardfail_2024_01_015 crossref_primary_10_1016_j_cardfail_2024_01_014 crossref_primary_10_1016_j_pcad_2024_01_010 crossref_primary_10_7759_cureus_29579 crossref_primary_10_1007_s00398_022_00544_4 crossref_primary_10_1080_03007995_2023_2223916 crossref_primary_10_1161_CIRCHEARTFAILURE_124_011980 crossref_primary_10_1139_cjpp_2023_0403 crossref_primary_10_1007_s00108_022_01394_w crossref_primary_10_1007_s11096_025_01908_0 crossref_primary_10_3390_ph17111419 crossref_primary_10_1038_s41591_022_01971_4 crossref_primary_10_1016_j_jaccao_2024_04_006 crossref_primary_10_1161_CIRCHEARTFAILURE_122_010161 crossref_primary_10_1161_CIRCHEARTFAILURE_122_010283 crossref_primary_10_1161_CIRCHEARTFAILURE_122_010280 crossref_primary_10_7759_cureus_30552 crossref_primary_10_1161_CIRCULATIONAHA_122_059725 crossref_primary_10_1097_FJC_0000000000001511 crossref_primary_10_3390_jcm11164640 crossref_primary_10_1007_s12181_022_00574_0 crossref_primary_10_1253_circj_CJ_25_0002 crossref_primary_10_1186_s12933_025_02767_9 crossref_primary_10_1007_s00059_022_05134_6 crossref_primary_10_3389_fped_2022_996946 crossref_primary_10_70389_PJBS_100009 crossref_primary_10_1007_s11883_022_01038_2 crossref_primary_10_7759_cureus_35030 crossref_primary_10_1093_eurheartj_ehaf057 crossref_primary_10_1161_CIRCHEARTFAILURE_123_011124 crossref_primary_10_1093_ckj_sfae195 crossref_primary_10_1161_CIRCULATIONAHA_122_061846 crossref_primary_10_1001_jamanetworkopen_2024_5135 crossref_primary_10_1177_15353702231198087 crossref_primary_10_1161_CIR_0000000000001122 crossref_primary_10_1016_j_cardfail_2022_03_345 crossref_primary_10_3390_ijms242417147 crossref_primary_10_4239_wjd_v13_i9_683 crossref_primary_10_1002_ejhf_3440 crossref_primary_10_1080_14779072_2022_2098118 crossref_primary_10_1016_j_cardfail_2022_03_350 crossref_primary_10_1161_CIRCULATIONAHA_122_057444 crossref_primary_10_1002_ehf2_14224 crossref_primary_10_1155_2023_8441396 crossref_primary_10_3390_jcm12216798 crossref_primary_10_1007_s10741_022_10267_1 crossref_primary_10_1016_j_ccl_2022_06_009 crossref_primary_10_1097_HCO_0000000000001021 crossref_primary_10_1016_j_ccl_2022_06_004 crossref_primary_10_1016_j_jcmg_2022_12_005 crossref_primary_10_1016_j_apsb_2024_12_040 crossref_primary_10_4103_jicc_jicc_65_24 crossref_primary_10_1007_s10741_023_10362_x crossref_primary_10_4239_wjd_v15_i7_1461 crossref_primary_10_1007_s11428_023_01144_y crossref_primary_10_1136_bmjopen_2024_092993 crossref_primary_10_3389_fphar_2022_919974 crossref_primary_10_1186_s13098_024_01446_1 crossref_primary_10_1186_s12933_022_01480_1 crossref_primary_10_3389_fphar_2022_877797 crossref_primary_10_1016_j_cpcardiol_2024_102839 crossref_primary_10_1161_CIRCULATIONAHA_123_065134 crossref_primary_10_1111_bph_16493 crossref_primary_10_1016_j_repc_2023_01_027 crossref_primary_10_1186_s12933_022_01526_4 crossref_primary_10_3389_fcvm_2022_910957 crossref_primary_10_1371_journal_pone_0326534 crossref_primary_10_1016_j_biopha_2022_113765 crossref_primary_10_1093_eurjpc_zwad400 crossref_primary_10_1007_s10741_025_10545_8 crossref_primary_10_3389_fcvm_2024_1403242 crossref_primary_10_1016_j_cardfail_2023_05_023 crossref_primary_10_1016_j_pharmthera_2023_108549 crossref_primary_10_36660_abchf_20220011 crossref_primary_10_1186_s12933_024_02398_6 crossref_primary_10_1159_000531432 crossref_primary_10_1080_14740338_2024_2412228 crossref_primary_10_3389_fcvm_2023_1143658 crossref_primary_10_1007_s40266_024_01165_2 crossref_primary_10_3389_fcvm_2023_1046194 crossref_primary_10_7759_cureus_75802 crossref_primary_10_1007_s40256_024_00669_x crossref_primary_10_3390_ijms23062991 crossref_primary_10_1016_j_jchf_2023_01_030 crossref_primary_10_1002_ehf2_14257 crossref_primary_10_1007_s11428_023_01047_y crossref_primary_10_1007_s11906_024_01296_2 crossref_primary_10_1016_j_jacadv_2024_101024 crossref_primary_10_1038_s41440_024_01649_z crossref_primary_10_1002_ejhf_2688 crossref_primary_10_3390_ijms23052812 crossref_primary_10_3389_fcvm_2022_903902 crossref_primary_10_1139_cjpp_2022_0154 crossref_primary_10_1038_s41392_022_01251_0 crossref_primary_10_1016_j_jchf_2024_02_018 crossref_primary_10_7759_cureus_72530 crossref_primary_10_1007_s11096_022_01504_6 crossref_primary_10_1053_j_ajkd_2022_09_016 crossref_primary_10_3390_ijms26062728 crossref_primary_10_1002_ejhf_2672 crossref_primary_10_3390_antiox11091822 crossref_primary_10_3390_healthcare10112133 crossref_primary_10_1016_j_jacc_2022_07_011 crossref_primary_10_1161_CIRCULATIONAHA_123_065061 crossref_primary_10_3390_life15071022 crossref_primary_10_1016_j_jchf_2022_08_007 crossref_primary_10_1186_s13643_025_02766_7 crossref_primary_10_1007_s13340_024_00723_8 crossref_primary_10_7759_cureus_92372 crossref_primary_10_3390_geriatrics7020036 crossref_primary_10_7759_cureus_45180 crossref_primary_10_1016_j_repc_2024_04_012 crossref_primary_10_2147_DMSO_S454876 crossref_primary_10_2337_dc24_S010 crossref_primary_10_1093_cvr_cvae047 crossref_primary_10_1093_eurheartj_ehaf027 crossref_primary_10_3390_ijms232315140 crossref_primary_10_1007_s12020_024_03758_8 crossref_primary_10_3389_fphar_2023_1111007 crossref_primary_10_1002_ehf2_14248 crossref_primary_10_1002_ejhf_2652 crossref_primary_10_1016_j_arr_2024_102467 crossref_primary_10_1002_ehf2_14005 crossref_primary_10_15829_1560_4071_2024_5690 crossref_primary_10_1002_ejhf_2535 crossref_primary_10_1002_ejhf_2778 crossref_primary_10_36660_abchf_20240048 crossref_primary_10_3389_fcvm_2023_1154447 crossref_primary_10_1080_14779072_2022_2057949 crossref_primary_10_3390_ijms231910989 crossref_primary_10_1016_j_diabres_2022_109871 crossref_primary_10_3389_fcvm_2022_1086672 crossref_primary_10_1007_s12181_022_00569_x crossref_primary_10_1371_journal_pone_0323634 crossref_primary_10_1093_cvr_cvae236 crossref_primary_10_1007_s13300_022_01278_0 crossref_primary_10_3389_fcvm_2022_942125 crossref_primary_10_3389_fcvm_2022_875327 crossref_primary_10_1161_CIRCHEARTFAILURE_122_009837 crossref_primary_10_1002_ejhf_2521 crossref_primary_10_1038_s41392_023_01400_z crossref_primary_10_1038_s41591_022_02041_5 crossref_primary_10_1002_ehf2_13760 crossref_primary_10_21518_ms2025_171 crossref_primary_10_3390_jcm13051375 crossref_primary_10_1186_s12933_024_02491_w crossref_primary_10_1016_j_ejim_2024_07_035 crossref_primary_10_1016_j_jacc_2023_04_003 crossref_primary_10_1161_CIRCULATIONAHA_124_069732 crossref_primary_10_3389_fphys_2022_906272 crossref_primary_10_3390_biomedicines10123294 crossref_primary_10_3389_fcvm_2023_1273781 crossref_primary_10_1007_s40256_025_00721_4 crossref_primary_10_1093_cvr_cvac166 crossref_primary_10_1016_j_pcad_2023_10_003 crossref_primary_10_1007_s10741_025_10504_3 crossref_primary_10_1093_eurjpc_zwad223 crossref_primary_10_1007_s10741_023_10315_4 crossref_primary_10_3389_fcvm_2023_1227769 crossref_primary_10_1007_s11897_022_00574_x crossref_primary_10_3389_fcvm_2021_809885 crossref_primary_10_7759_cureus_34687 crossref_primary_10_1016_j_repc_2023_05_012 crossref_primary_10_2459_JCM_0000000000001411 crossref_primary_10_3390_jcm11195956 crossref_primary_10_3904_kjim_2022_271 crossref_primary_10_1016_j_cmet_2023_08_003 crossref_primary_10_1136_heartjnl_2022_321097 crossref_primary_10_1016_j_lfs_2024_122594 crossref_primary_10_2337_dc25_S010 crossref_primary_10_1097_CRD_0000000000000454 crossref_primary_10_3389_fcvm_2023_1226586 crossref_primary_10_3390_jcm12030802 crossref_primary_10_1016_j_eprac_2022_08_002 crossref_primary_10_1161_CIRCHEARTFAILURE_124_012349 crossref_primary_10_1186_s12872_024_04078_5 crossref_primary_10_3389_fcvm_2025_1556606 crossref_primary_10_1016_j_ijcha_2024_101539 crossref_primary_10_1097_MD_0000000000028448 crossref_primary_10_3928_00989134_20220908_01 crossref_primary_10_3390_jcm12206698 crossref_primary_10_3390_pharmaceutics14091964 crossref_primary_10_1016_j_heliyon_2024_e27110 crossref_primary_10_1111_jdi_14202 crossref_primary_10_1161_CIRCULATIONAHA_124_068788 crossref_primary_10_1002_ejhf_2738 crossref_primary_10_1002_ejhf_2615 crossref_primary_10_1161_CIRCULATIONAHA_122_060348 crossref_primary_10_1111_jdi_70056 crossref_primary_10_3390_jcm14103598 crossref_primary_10_1007_s10741_022_10285_z crossref_primary_10_1016_S0140_6736_22_01429_5 crossref_primary_10_3390_cimb46090571 crossref_primary_10_1161_CIRCULATIONAHA_121_057812 crossref_primary_10_1007_s10741_023_10324_3 crossref_primary_10_1007_s12265_022_10302_4 crossref_primary_10_1155_2023_1552826 crossref_primary_10_1016_j_ijcard_2022_10_009 crossref_primary_10_1016_j_ijcard_2023_02_021 crossref_primary_10_1016_j_jacc_2022_11_006 crossref_primary_10_3390_ijms26146937 crossref_primary_10_1007_s11897_023_00626_w crossref_primary_10_1161_CIR_0000000000001168 crossref_primary_10_1016_j_ejim_2023_04_022 crossref_primary_10_1093_cvr_cvac120 crossref_primary_10_1161_JAHA_124_039105 crossref_primary_10_1186_s12933_023_02023_y crossref_primary_10_1016_j_jchf_2024_04_017 crossref_primary_10_1007_s13340_022_00605_x crossref_primary_10_1002_ejhf_2831 crossref_primary_10_1007_s10741_025_10526_x crossref_primary_10_7759_cureus_81512 crossref_primary_10_3390_pharmacy10060166 crossref_primary_10_1016_j_amjmed_2024_10_026 crossref_primary_10_7759_cureus_81757 crossref_primary_10_1093_postmj_qgae148 crossref_primary_10_1007_s11897_024_00679_5 crossref_primary_10_1016_j_diabres_2022_109927 crossref_primary_10_1007_s42000_025_00702_x crossref_primary_10_1186_s44348_024_00043_0 crossref_primary_10_1161_JAHA_123_032646 crossref_primary_10_4239_wjd_v15_i2_137 crossref_primary_10_1016_j_jchf_2023_03_011 crossref_primary_10_1016_j_biopha_2024_116994 crossref_primary_10_1038_s41591_022_01703_8 crossref_primary_10_1016_j_isci_2025_113471 crossref_primary_10_1016_j_jacc_2022_11_032 crossref_primary_10_1186_s12933_023_01946_w crossref_primary_10_3390_jcdd10070274 crossref_primary_10_1183_23120541_00714_2023 crossref_primary_10_5694_mja2_51656 crossref_primary_10_1161_CIRCULATIONAHA_122_059280 crossref_primary_10_1161_CIRCHEARTFAILURE_122_009867 crossref_primary_10_1007_s10741_023_10338_x crossref_primary_10_1016_S0140_6736_22_00016_2 crossref_primary_10_1161_JAHA_122_029058 crossref_primary_10_1038_s41591_024_03140_1 crossref_primary_10_1177_10600280231154021 crossref_primary_10_3389_fimmu_2022_947147 crossref_primary_10_1007_s40272_024_00623_z crossref_primary_10_1016_j_jchf_2023_05_010 crossref_primary_10_1080_14656566_2023_2204188 crossref_primary_10_1182_blood_2022017201 crossref_primary_10_3390_biomedicines11082236 crossref_primary_10_1093_ehjcvp_pvad088 crossref_primary_10_3389_fcvm_2025_1482918 crossref_primary_10_1016_j_ijcrp_2022_200161 crossref_primary_10_1016_j_cardfail_2022_07_001 crossref_primary_10_1016_j_jacc_2023_02_012 crossref_primary_10_3389_fphar_2021_787704 crossref_primary_10_1016_j_matbio_2024_02_008 crossref_primary_10_1097_XCE_0000000000000284 crossref_primary_10_1016_j_amjmed_2023_04_019 crossref_primary_10_1080_17512433_2022_2108402 crossref_primary_10_1016_j_yjmcc_2022_04_005 crossref_primary_10_1016_j_jacadv_2025_101972 crossref_primary_10_3389_fcvm_2022_926979 crossref_primary_10_3389_fsysb_2025_1593229 crossref_primary_10_1186_s12872_022_02693_8 crossref_primary_10_1016_j_amjmed_2023_04_035 crossref_primary_10_1093_eurheartj_ehac481 crossref_primary_10_1016_j_cpcardiol_2024_102388 crossref_primary_10_2174_0118741924374806250704064226 crossref_primary_10_33590_emj_22_00026 crossref_primary_10_3390_pharmaceutics15041092 crossref_primary_10_7759_cureus_78570 crossref_primary_10_1016_j_jacc_2024_08_061 crossref_primary_10_1016_j_jacadv_2025_101839 crossref_primary_10_1515_tjb_2024_0240 crossref_primary_10_1016_j_exger_2024_112445 crossref_primary_10_1007_s10741_022_10228_8 crossref_primary_10_1016_j_jacc_2022_01_028 crossref_primary_10_1016_j_jacc_2023_03_393 crossref_primary_10_1007_s00228_024_03660_2 crossref_primary_10_1161_CIRCHEARTFAILURE_121_009124 crossref_primary_10_3389_fcvm_2022_1041200 crossref_primary_10_1111_jce_15996 crossref_primary_10_1161_CIRCHEARTFAILURE_123_010633 crossref_primary_10_1111_jvp_13472 crossref_primary_10_1186_s12933_025_02774_w crossref_primary_10_1038_s41569_022_00717_6 crossref_primary_10_1097_HCO_0000000000000953 crossref_primary_10_1186_s12933_025_02750_4 crossref_primary_10_1016_j_hrthm_2024_12_038 crossref_primary_10_3389_fcvm_2023_1099453 crossref_primary_10_1002_ehf2_14810 crossref_primary_10_1007_s10741_023_10366_7 crossref_primary_10_1080_17425255_2022_2105693 crossref_primary_10_1016_j_jacadv_2025_101701 crossref_primary_10_1016_j_jjcc_2023_06_008 crossref_primary_10_1001_jama_2023_2020 crossref_primary_10_1001_jama_2023_1053 crossref_primary_10_1038_s41591_021_01565_6 crossref_primary_10_1007_s40265_022_01778_0 crossref_primary_10_1161_CIRCULATIONAHA_124_070248 crossref_primary_10_1080_14779072_2023_2159810 crossref_primary_10_1007_s10741_022_10280_4 crossref_primary_10_1016_j_cpcardiol_2024_102372 crossref_primary_10_5937_scriptamed56_56443 crossref_primary_10_1038_s43856_025_00951_2 crossref_primary_10_1093_ehjimp_qyaf023 crossref_primary_10_1161_CIRCULATIONAHA_124_072679 crossref_primary_10_1007_s00210_023_02590_7 crossref_primary_10_1080_13697137_2023_2250252 crossref_primary_10_5334_gh_1258 crossref_primary_10_1016_j_shj_2022_100090 crossref_primary_10_1111_jdi_13960 crossref_primary_10_3390_jcm11071904 crossref_primary_10_3390_biomedicines12071572 crossref_primary_10_3390_biom12020278 crossref_primary_10_3390_biomedicines13061413 crossref_primary_10_3390_ijms242015160 crossref_primary_10_3390_pharmaceutics14081730 crossref_primary_10_1016_j_kjs_2025_100438 crossref_primary_10_1007_s11886_023_01961_z crossref_primary_10_1016_j_jacc_2024_06_036 crossref_primary_10_1186_s12933_023_02042_9 crossref_primary_10_1038_s41569_021_00650_0 crossref_primary_10_3389_fendo_2023_1079626 |
| Cites_doi | 10.1016/j.jacbts.2018.07.006 10.1016/S0735-1097(00)00531-3 10.1161/CIRCHEARTFAILURE.114.001615 10.1056/NEJMoa2030183 10.1161/CIRCULATIONAHA.116.026807 10.1161/CIR.0000000000000483 10.1002/ejhf.1788 10.1161/CIR.0000000000000691 10.1161/CIRCULATIONAHA.120.052503 10.1016/j.jacbts.2019.04.003 10.1038/nrcardio.2017.65 10.1592/phco.20.7.679.35178 10.1016/S1053-2498(01)00298-4 10.1016/j.jchf.2019.05.015 10.1161/CIRCINTERVENTIONS.119.008051 10.1161/CIRCRESAHA.119.313572 10.1007/BF02599287 10.1038/s41569-020-0406-8 10.1002/ejhf.2064 10.1093/eurheartj/ehaa943 10.1056/NEJMoa2022190 10.1016/j.jacc.2020.07.009 10.1002/ejhf.976 10.1016/j.jacc.2012.12.044 10.1016/j.ejphar.2019.172810 10.1002/ejhf.2249 10.1161/CIRCULATIONAHA.119.042929 10.1056/NEJMoa1911303 10.1056/NEJMoa1908655 10.1093/eurheartj/ehy531 10.1161/CIRCHEARTFAILURE.118.005254 10.1016/j.jacc.2021.07.014 10.1161/CIRCHEARTFAILURE.114.001937 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 Nature Publishing Group The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 Nature Publishing Group – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7X7 7XB 88A 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M2P M7N M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM |
| DOI | 10.1038/s41591-021-01536-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Proquest Health & Medical Complete ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals ProQuest SciTech Collection ProQuest Medical Library Animal Behavior Abstracts Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1546-170X |
| EndPage | 1960 |
| ExternalDocumentID | PMC8604725 A683288493 34711976 10_1038_s41591_021_01536_x |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: AstraZeneca Study Number: ESR-16-12141 – fundername: ; |
| GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 3V. 4.4 53G 5BI 5M7 5RE 5S5 70F 7X7 85S 88A 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAEEF AARCD AAYOK AAYZH AAZLF ABAWZ ABCQX ABDBF ABDPE ABEFU ABJNI ABLJU ABOCM ABUWG ACBWK ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ACUHS ADBBV ADFRT AENEX AEUYN AFBBN AFKRA AFRAH AFSHS AGAYW AGCDD AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CCPQU CS3 DB5 DU5 DWQXO EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH GX1 HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M0L M1P M2O M2P M7P MK0 N9A NADUK NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SOJ SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M AAYXX ABFSG ACSTC AEZWR AFANA AFFHD AFHIU AGSTI AHWEU AIXLP ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY PQGLB XRW AETEA CGR CUY CVF ECM EIF NFIDA NPM ACMFV 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c678t-9a0b721309e57cb0df3589b5bfcfa48de0564151c7d7e5948a9aad9f2acd16a13 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 433 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000712353600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-8956 1546-170X |
| IngestDate | Tue Nov 04 02:00:09 EST 2025 Thu Sep 04 17:24:57 EDT 2025 Mon Oct 06 17:28:47 EDT 2025 Sat Nov 29 12:59:41 EST 2025 Sat Nov 29 11:43:53 EST 2025 Sat Nov 29 10:14:51 EST 2025 Wed Nov 26 10:11:48 EST 2025 Wed Nov 26 10:12:51 EST 2025 Thu May 22 21:06:37 EDT 2025 Mon Jul 21 05:40:18 EDT 2025 Sat Nov 29 06:02:29 EST 2025 Tue Nov 18 22:01:32 EST 2025 Fri Feb 21 02:37:42 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | 2021. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c678t-9a0b721309e57cb0df3589b5bfcfa48de0564151c7d7e5948a9aad9f2acd16a13 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-0874-7059 0000-0001-9375-0596 0000-0002-5655-8201 0000-0002-3750-9789 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8604725 |
| PMID | 34711976 |
| PQID | 2599272280 |
| PQPubID | 33975 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604725 proquest_miscellaneous_2590124951 proquest_journals_2599272280 gale_infotracmisc_A683288493 gale_infotracgeneralonefile_A683288493 gale_infotracacademiconefile_A683288493 gale_incontextgauss_ISR_A683288493 gale_incontextgauss_IOV_A683288493 gale_healthsolutions_A683288493 pubmed_primary_34711976 crossref_primary_10_1038_s41591_021_01536_x crossref_citationtrail_10_1038_s41591_021_01536_x springer_journals_10_1038_s41591_021_01536_x |
| PublicationCentury | 2000 |
| PublicationDate | 2021-11-01 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Nature medicine |
| PublicationTitleAbbrev | Nat Med |
| PublicationTitleAlternate | Nat Med |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | McMurray (CR11) 2019; 381 Cowie, Fisher (CR13) 2020; 17 Dunlay, Roger, Redfield (CR1) 2017; 14 van Veldhuisen (CR35) 2013; 61 Pfeffer, Shah, Borlaug (CR2) 2019; 124 CR15 Shah (CR32) 2018; 39 Warraich (CR3) 2018; 11 Verma (CR30) 2018; 3 Abraham (CR21) 2021; 42 Anker (CR20) 2020; 22 Bhatt (CR14) 2020; 384 Nassif (CR10) 2019; 140 Tsevat (CR5) 1994; 9 Reddy (CR8) 2020; 22 Forman (CR25) 2017; 135 Pandey (CR27) 2015; 8 Nassif (CR28) 2021; 143 Obokata, Reddy, Pislaru, Melenovsky, Borlaug (CR34) 2017; 136 Packer (CR12) 2020; 383 Green, Porter, Bresnahan, Spertus (CR36) 2000; 35 Lewis (CR6) 2001; 20 Guyatt (CR37) 1985; 132 CR7 CR26 Nambu (CR33) 2020; 866 CR23 Reddy, Obokata, Verbrugge, Lin, Borlaug (CR22) 2020; 76 Solomon (CR17) 2021; 23 Wolsk (CR29) 2018; 20 Reed (CR24) 2019; 12 Dunlay (CR9) 2019; 140 Reddy, Dunn (CR4) 2000; 20 Juni (CR31) 2019; 4 Chandra (CR16) 2019; 7 Solomon (CR19) 2019; 381 Lewis (CR18) 2016; 9 1536_CR7 DL Bhatt (1536_CR14) 2020; 384 DE Forman (1536_CR25) 2017; 135 SM Dunlay (1536_CR1) 2017; 14 EF Lewis (1536_CR6) 2001; 20 ME Nassif (1536_CR28) 2021; 143 S Verma (1536_CR30) 2018; 3 H Nambu (1536_CR33) 2020; 866 MR Cowie (1536_CR13) 2020; 17 WT Abraham (1536_CR21) 2021; 42 E Wolsk (1536_CR29) 2018; 20 A Pandey (1536_CR27) 2015; 8 EF Lewis (1536_CR18) 2016; 9 SD Reed (1536_CR24) 2019; 12 P Reddy (1536_CR4) 2000; 20 M Obokata (1536_CR34) 2017; 136 DJ van Veldhuisen (1536_CR35) 2013; 61 GH Guyatt (1536_CR37) 1985; 132 1536_CR15 CP Green (1536_CR36) 2000; 35 MA Pfeffer (1536_CR2) 2019; 124 SM Dunlay (1536_CR9) 2019; 140 SJ Shah (1536_CR32) 2018; 39 HJ Warraich (1536_CR3) 2018; 11 A Chandra (1536_CR16) 2019; 7 YNV Reddy (1536_CR8) 2020; 22 JJV McMurray (1536_CR11) 2019; 381 YNV Reddy (1536_CR22) 2020; 76 ME Nassif (1536_CR10) 2019; 140 M Packer (1536_CR12) 2020; 383 RP Juni (1536_CR31) 2019; 4 J Tsevat (1536_CR5) 1994; 9 SD Solomon (1536_CR19) 2019; 381 SD Anker (1536_CR20) 2020; 22 1536_CR23 SD Solomon (1536_CR17) 2021; 23 1536_CR26 34764484 - Nat Med. 2021 Nov;27(11):1872-1873. doi: 10.1038/s41591-021-01565-6 34815543 - Nat Rev Cardiol. 2022 Jan;19(1):6. doi: 10.1038/s41569-021-00650-0 |
| References_xml | – volume: 3 start-page: 575 year: 2018 end-page: 587 ident: CR30 article-title: Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2018.07.006 – volume: 35 start-page: 1245 year: 2000 end-page: 1255 ident: CR36 article-title: Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure publication-title: J. Am. Coll. Cardiol. doi: 10.1016/S0735-1097(00)00531-3 – volume: 8 start-page: 33 year: 2015 end-page: 40 ident: CR27 article-title: Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials publication-title: Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.114.001615 – volume: 11 start-page: e005254 year: 2018 ident: CR3 article-title: Physical function, frailty, cognition, depression, and quality of life in hospitalized adults ≥60 years with acute decompensated heart failure with preserved versus reduced ejection fraction publication-title: Circ. Heart Fail. – volume: 384 start-page: 117 year: 2020 end-page: 128 ident: CR14 article-title: Sotagliflozin in patients with diabetes and recent worsening heart failure publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2030183 – volume: 132 start-page: 919 year: 1985 end-page: 923 ident: CR37 article-title: The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure publication-title: Can. Med. Assoc. J. – volume: 9 start-page: e001937 year: 2016 ident: CR18 article-title: Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial publication-title: Circ. Heart Fail. – volume: 136 start-page: 6 year: 2017 end-page: 19 ident: CR34 article-title: Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.026807 – volume: 135 start-page: e894 year: 2017 end-page: e918 ident: CR25 article-title: Prioritizing functional capacity as a principal end point for therapies oriented to older adults with cardiovascular disease: a scientific statement for healthcare professionals from the American Heart Association publication-title: Circulation doi: 10.1161/CIR.0000000000000483 – volume: 22 start-page: 1009 year: 2020 end-page: 1018 ident: CR8 article-title: Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.1788 – volume: 140 start-page: e294 year: 2019 end-page: e324 ident: CR9 article-title: Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update publication-title: Circulation doi: 10.1161/CIR.0000000000000691 – volume: 143 start-page: 1673 year: 2021 end-page: 1686 ident: CR28 article-title: Empagliflozin effects on pulmonary artery pressure in patients with heart failure publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.052503 – volume: 4 start-page: 575 year: 2019 end-page: 591 ident: CR31 article-title: Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2019.04.003 – volume: 14 start-page: 591 year: 2017 end-page: 602 ident: CR1 article-title: Epidemiology of heart failure with preserved ejection fraction publication-title: Nat. Rev. Cardiol. doi: 10.1038/nrcardio.2017.65 – ident: CR23 – volume: 20 start-page: 679 year: 2000 end-page: 689 ident: CR4 article-title: The effect of beta-blockers on health-related quality of life in patients with heart failure publication-title: Pharmacotherapy doi: 10.1592/phco.20.7.679.35178 – volume: 20 start-page: 1016 year: 2001 end-page: 1024 ident: CR6 article-title: Preferences for quality of life or survival expressed by patients with heart failure publication-title: J. Heart Lung Transplant. doi: 10.1016/S1053-2498(01)00298-4 – volume: 7 start-page: 862 year: 2019 end-page: 874 ident: CR16 article-title: Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial publication-title: JACC Heart Fail. doi: 10.1016/j.jchf.2019.05.015 – volume: 12 start-page: e008051 year: 2019 ident: CR24 article-title: Patients’ willingness to accept mitral valve procedure-associated risks varies across severity of heart failure symptoms publication-title: Circ. Cardiovasc. Interv. doi: 10.1161/CIRCINTERVENTIONS.119.008051 – volume: 124 start-page: 1598 year: 2019 end-page: 1617 ident: CR2 article-title: Heart failure with preserved ejection fraction in perspective publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.119.313572 – volume: 9 start-page: 576 year: 1994 end-page: 582 ident: CR5 article-title: Using health-related quality-of-life information: clinical encounters, clinical trials, and health policy publication-title: J. Gen. Intern. Med. doi: 10.1007/BF02599287 – ident: CR15 – volume: 17 start-page: 761 year: 2020 end-page: 772 ident: CR13 article-title: SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-020-0406-8 – volume: 22 start-page: 2383 year: 2020 end-page: 2392 ident: CR20 article-title: Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.2064 – volume: 42 start-page: 700 year: 2021 end-page: 710 ident: CR21 article-title: Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehaa943 – volume: 383 start-page: 1413 year: 2020 end-page: 1424 ident: CR12 article-title: EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022190 – volume: 76 start-page: 1051 year: 2020 end-page: 1064 ident: CR22 article-title: Atrial dysfunction in patients with heart failure with preserved ejection fraction and atrial fibrillation publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.07.009 – volume: 20 start-page: 715 year: 2018 end-page: 722 ident: CR29 article-title: Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.976 – volume: 61 start-page: 1498 year: 2013 end-page: 1506 ident: CR35 article-title: B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2012.12.044 – volume: 866 start-page: 172810 year: 2020 ident: CR33 article-title: Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2019.172810 – ident: CR7 – volume: 23 start-page: 1217 year: 2021 end-page: 1225 ident: CR17 article-title: Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.2249 – volume: 140 start-page: 1463 year: 2019 end-page: 1476 ident: CR10 article-title: Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.042929 – volume: 381 start-page: 1995 year: 2019 end-page: 2008 ident: CR11 article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911303 – volume: 381 start-page: 1609 year: 2019 end-page: 1620 ident: CR19 article-title: Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1908655 – ident: CR26 – volume: 39 start-page: 3439 year: 2018 end-page: 3450 ident: CR32 article-title: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehy531 – volume: 11 start-page: e005254 year: 2018 ident: 1536_CR3 publication-title: Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.118.005254 – volume: 4 start-page: 575 year: 2019 ident: 1536_CR31 publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2019.04.003 – volume: 39 start-page: 3439 year: 2018 ident: 1536_CR32 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehy531 – volume: 381 start-page: 1609 year: 2019 ident: 1536_CR19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1908655 – volume: 135 start-page: e894 year: 2017 ident: 1536_CR25 publication-title: Circulation doi: 10.1161/CIR.0000000000000483 – volume: 140 start-page: 1463 year: 2019 ident: 1536_CR10 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.119.042929 – ident: 1536_CR23 doi: 10.1016/j.jacc.2021.07.014 – volume: 12 start-page: e008051 year: 2019 ident: 1536_CR24 publication-title: Circ. Cardiovasc. Interv. doi: 10.1161/CIRCINTERVENTIONS.119.008051 – volume: 76 start-page: 1051 year: 2020 ident: 1536_CR22 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2020.07.009 – volume: 9 start-page: e001937 year: 2016 ident: 1536_CR18 publication-title: Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.114.001937 – volume: 9 start-page: 576 year: 1994 ident: 1536_CR5 publication-title: J. Gen. Intern. Med. doi: 10.1007/BF02599287 – volume: 866 start-page: 172810 year: 2020 ident: 1536_CR33 publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2019.172810 – volume: 20 start-page: 679 year: 2000 ident: 1536_CR4 publication-title: Pharmacotherapy doi: 10.1592/phco.20.7.679.35178 – volume: 20 start-page: 1016 year: 2001 ident: 1536_CR6 publication-title: J. Heart Lung Transplant. doi: 10.1016/S1053-2498(01)00298-4 – volume: 20 start-page: 715 year: 2018 ident: 1536_CR29 publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.976 – volume: 22 start-page: 2383 year: 2020 ident: 1536_CR20 publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.2064 – volume: 124 start-page: 1598 year: 2019 ident: 1536_CR2 publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.119.313572 – volume: 23 start-page: 1217 year: 2021 ident: 1536_CR17 publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.2249 – volume: 381 start-page: 1995 year: 2019 ident: 1536_CR11 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911303 – volume: 17 start-page: 761 year: 2020 ident: 1536_CR13 publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-020-0406-8 – ident: 1536_CR26 – volume: 42 start-page: 700 year: 2021 ident: 1536_CR21 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehaa943 – volume: 3 start-page: 575 year: 2018 ident: 1536_CR30 publication-title: JACC Basic Transl. Sci. doi: 10.1016/j.jacbts.2018.07.006 – ident: 1536_CR15 – ident: 1536_CR7 – volume: 140 start-page: e294 year: 2019 ident: 1536_CR9 publication-title: Circulation doi: 10.1161/CIR.0000000000000691 – volume: 384 start-page: 117 year: 2020 ident: 1536_CR14 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2030183 – volume: 22 start-page: 1009 year: 2020 ident: 1536_CR8 publication-title: Eur. J. Heart Fail. doi: 10.1002/ejhf.1788 – volume: 35 start-page: 1245 year: 2000 ident: 1536_CR36 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/S0735-1097(00)00531-3 – volume: 136 start-page: 6 year: 2017 ident: 1536_CR34 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.026807 – volume: 14 start-page: 591 year: 2017 ident: 1536_CR1 publication-title: Nat. Rev. Cardiol. doi: 10.1038/nrcardio.2017.65 – volume: 7 start-page: 862 year: 2019 ident: 1536_CR16 publication-title: JACC Heart Fail. doi: 10.1016/j.jchf.2019.05.015 – volume: 132 start-page: 919 year: 1985 ident: 1536_CR37 publication-title: Can. Med. Assoc. J. – volume: 383 start-page: 1413 year: 2020 ident: 1536_CR12 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022190 – volume: 8 start-page: 33 year: 2015 ident: 1536_CR27 publication-title: Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.114.001615 – volume: 61 start-page: 1498 year: 2013 ident: 1536_CR35 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2012.12.044 – volume: 143 start-page: 1673 year: 2021 ident: 1536_CR28 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.052503 – reference: 34815543 - Nat Rev Cardiol. 2022 Jan;19(1):6. doi: 10.1038/s41569-021-00650-0 – reference: 34764484 - Nat Med. 2021 Nov;27(11):1872-1873. doi: 10.1038/s41591-021-01565-6 |
| SSID | ssj0003059 |
| Score | 2.7291393 |
| Snippet | Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life.... In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1954 |
| SubjectTerms | 692/308/409 692/699/75/230 Adverse events Aged Antidiabetics Benzhydryl Compounds - adverse effects Benzhydryl Compounds - therapeutic use Biomedical and Life Sciences Biomedicine Blood pressure Cancer Research Cardiac output Cardiac patients Cardiomyopathy Care and treatment Confidence intervals Congestive heart failure Dapagliflozin Diagnosis Double-Blind Method Ejection fraction Exercise - physiology Female Glucosides - adverse effects Glucosides - therapeutic use Health Status Heart failure Heart Failure - drug therapy Hemoglobin Humans Infectious Diseases Inhibitors Male Measurement Metabolic Diseases Middle Aged Molecular Medicine Neurosciences Patients Peptides Placebos Placebos - administration & dosage Quality of life Quality of Life - psychology Risk factors Sodium-glucose cotransporter Sodium-Glucose Transporter 2 - drug effects Sodium-Glucose Transporter 2 - metabolism Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Stroke Volume - drug effects Surveys and Questionnaires Testing Weight reduction |
| Title | The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial |
| URI | https://link.springer.com/article/10.1038/s41591-021-01536-x https://www.ncbi.nlm.nih.gov/pubmed/34711976 https://www.proquest.com/docview/2599272280 https://www.proquest.com/docview/2590124951 https://pubmed.ncbi.nlm.nih.gov/PMC8604725 |
| Volume | 27 |
| WOSCitedRecordID | wos000712353600002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M7P dateStart: 20200101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: BENPR dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: 7X7 dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2O dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1546-170X dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2P dateStart: 20200101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYB4gXPsZXYAyDEDxAtCTOh80LGmgDJLZV20B9ixzH6YJKMpoWjf313DluRiqYkHiJ1PpnKfad7y72-XeEPONBWHhFzFxwrcINZZi7XES5G_rc41oJprUyxSaSvT0-Gomh3XBrbFrlwiYaQ53XCvfINyFMF0GC5C1vTr67WDUKT1dtCY0VsopMZeGArL7d3hsedLYYtFm0WYcc3yG212Y8xjcbcF2Y9RPg53TEYve055qWDfRvHmo5e3LpCNV4pp0b_zumm-S6jUnpVqtEt8glXa2RK22Vyp9r5OquPX-_TRrQKnr4_tNRQMvquMzAHExpDv52PCmLSX1WVvA_xSLZM1rIElPeKe70Uky3xdzKnOqvJvmrosW0vVPxmkpq0hpxpHpKwXnm9bfyDLCmpMgd8nln--jdB9eWbXAVeL6ZK6SXwXcl84SOEpV5ecEiLrIoK1QhQ55riLlg7n2V5IlGthgppMxFEUiV-7H02V0yqOpK3yeUhZFQieDQASKnrJBJoUOZMSmU52XKd4i_kFiqLKc5ltaYpOZsnfG0lXIKUk6NlNNTh7zs-py0jB4Xoh-jIqTtrdTOHKRbMZhCzkPBHPLUIJBMo8JsnbGcN036cf_LP4AOD3qgFxZU1DAKJe0NCZgLJOnqIZ_3kOOWovxPwPUeEGyH6jcvFDO1tqtJz7XSIU-6ZuyJ-XiVrucG45my5SCCe-1y6CaTQbzjQ5TrkKS3UDoAMpr3W6ry2DCb8xjJSyOHvFosqfPX-ruMHlw8iofkWoCr3FwgXSeD2XSuH5HL6sesbKYbZCUZJebJN6z1gF-7wb55DvGZDH8BDD52jQ |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLZKWS8sZQsUahDLAaJmj42EUAWUjjptER3Q3ILjONOgISmTGWj7o_iNvOcsJSOouPTAdfw5Gttvc_K99wh5xBwvtdLANcG1ctMTXmIy7iemZzOLKcldpaRuNhFub7PhkL9fID-bXBikVTY2URvqpJD4jnwVwnTuhFi85dX-NxO7RuHX1aaFRiUWm-rwB1zZype9N3C-jx1n_e3g9YZZdxUwJRjmqcmFFcO1x7W48kMZW0nq-ozHfpzKVHgsURASgFezZZiECouZCC5EwlNHyMQOhO3Cc8-Qs2DHQ6SQhcP2goe6wyuOI8MVB3WSjuWy1RIeiRwjBy_vvhuYBx1HOO8OfvOH81zNuQ-22g-uX_nfdvAquVxH3HStUpFrZEHlS-R81YPzcIlc2KrZBddJCTpDd9_1Bw7N8r0sBmM3oQlEE6Nxlo6LoyyH3ym2AJ_SVGRI6Kf4HpsimRiZowlVXzS1LafppMoYeUEF1aRN3Fk1oRAaJMXX7AiwumHKDfLxVBZ_kyzmRa5uE-p6PpchZzAB4sI4FWGqPBG7gkvLiqVtELuRkEjWFduxccg40swBl0WVVEUgVZGWqujAIM_aOftVvZIT0SsoeFGVc9sau2gtAEPPmMddgzzUCCwVkiMXaSRmZRn1dj79A2j3Qwf0tAalBaxCijr_A_YCS5B1kE86yFFVgP1PwOUOECyj7A43ihDVlrmMjrXAIA_aYZyJbMNcFTONsXRTdjiCW5X6tZvpQjRnQwxvkLCjmC0A67V3R_JsT9dtZwGWZvUN8rxR4eO_9fczunPyKlbIxY3BVj_q97Y375JLDloYnSq7TBank5m6R87J79OsnNzXtoqSz6et2r8Ak_vO9Q |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGgIkXLuNWGMwgLg8QNffYSAhNjMK0rVRsoL0Fx7G7oJKMpoVtP41fxzlOmpEKJl72wGv9Oartc3PynXMIecRcX9s69CxwrdzyhZ9ajAep5TvMZkpyTylpmk1E_T7b2-ODBfJzlguDtMqZTTSGOi0kviPvQpjO3QiLt3R1TYsYrPdeHXyzsIMUfmmdtdOoRGRTHf2A61v5cmMdzvqx6_be7L5-Z9UdBiwJRnpicWEncAXybK6CSCZ2qr2A8SRItNTCZ6mC8AA8nCOjNFJY2ERwIVKuXSFTJxSOB889R85HfhCgdm27g8YLgB7xiu_IcPVhnbBje6xbwiORb-TiRT7wQuuw5RTnXcNvvnGetzn38db4xN6V_3k3r5LLdSRO1yrVuUYWVL5MLla9OY-WydJ2zTq4TkrQJbrzdmvXpVm-nyVgBMc0hShjOMr0qDjOcvidYmvwCdUiQ6I_xffbFEnGyChNqfpiKG851eMqk-QFFdSQOXGX1ZhCyJAWX7NjwJpGKjfIxzNZ_E2ymBe5uk2o5wdcRpzBBIgXEy0irXyReIJL206k0yHOTFpiWVdyx4Yio9gwCjwWVxIWg4TFRsLiww551sw5qOqYnIpeRSGMq1zcxgjGayE4AMZ87nXIQ4PAEiI5is9QTMsy3nj_6R9AOx9aoKc1SBewCinqvBDYCyxN1kI-aSGHVWH2PwFXWkCwmLI9PFOKuLbYZXyiER3yoBnGmchCzFUxNRjbNGuHI7hVqWKzmR5EeQ7E9h0StZS0AWAd9_ZInu2beu4sxJKtQYc8n6nzyd_6-xndOX0Vq2QJNDre2uhv3iWXXDQ2JoN2hSxOxlN1j1yQ3ydZOb5vzBYln89as38BfezXwg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+SGLT2+inhibitor+dapagliflozin+in+heart+failure+with+preserved+ejection+fraction%3A+a+multicenter+randomized+trial&rft.jtitle=Nature+medicine&rft.au=Nassif%2C+Michael+E&rft.au=Windsor%2C+Sheryl+L&rft.au=Borlaug%2C+Barry+A&rft.au=Kitzman%2C+Dalane+W&rft.date=2021-11-01&rft.pub=Nature+Publishing+Group&rft.issn=1078-8956&rft.volume=27&rft.issue=11&rft.spage=1954&rft_id=info:doi/10.1038%2Fs41591-021-01536-x&rft.externalDBID=IOV&rft.externalDocID=A683288493 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-8956&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-8956&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-8956&client=summon |